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effectiveness analysis is conducted from a societal perspective
(direct and indirect costs) and from a health care perspective
(direct costs only). Direct costs include pharmaceuticals and phy-
sician visits. Indirect costs are calculated based on production
losses (the human capital approach). The analysis uses a cost-
effectiveness model which includes effect data from two clinical
studies of gabapentin and one clinical study of pregabalin previ-
ously used in a Canadian cost-effectiveness analysis. In addition,
the analysis and treatment doses are partly based on two clinical
studies of pregabalin and gabapentin. Resource use is based on
time spent in each pain state (mild, moderate, and severe). In the
sensitivity analysis drug doses, costs, and quality of life weights
were varied. Information regarding costs, resource use, and
quality of life weights was collected from the Canadian study,
Statistics Sweden, regional price lists, Pharmaceutical Specialties
in Sweden, and from three burden of illness studies. Dr. Jörgen
Boivie was consulted regarding Swedish treatment practice.
RESULTS: Since patients treated with pregabalin spend less time
in the more severe pain states their health in terms of QALY’s is
better compared to patients treated with gabapentin (0.5019 vs.
0.4596). In the societal perspective analysis, total costs of one
year treatment were lower for pregabalin than for gabapentin
(SEK100, 476 vs. SEK102, 103). Total costs were only slightly
higher for pregabalin (SEK57,811 vs. SEK52, 645) and the cost
per QALY gained was estimated to be SEK120,000 when indirect
costs were excluded. CONCLUSION: The study shows that
pregabalin is a cost-effective and, from a societal perspective, a
cost-saving alternative compared to gabapentin in treatment of
patients with PHN.
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OBJECTIVE: To assess the cost-effectiveness of laparoscopic
adjustable gastric banding (LAGB) as treatment for morbid
obesity compared with laparoscopic roux-en-y gastric bypass
(LRGBY) and no treatment. METHODS: A Markov model was
developed to simulate weight loss, health consequences, and
costs for surgical treatment of morbid obesity. The model was
used to estimate lifetime medical-care costs, quality-adjusted life
years (QALYs) and incremental cost-effectiveness ratios (ICERs)
in terms of cost per QALY gained. Estimates of effectiveness were
derived from published results of a head-to-head randomized
controlled trial comparing LAGB and LRGBY. Patients receiving
no treatment were assumed to maintain their original weight.
Other model parameters, including complication rates, costs of
treatment and adverse events, direct medical costs attributable to
obesity, mortality rates, and utilities, were estimated from pub-
lished literature and publicly available databases. Base-case
analyses were stratiﬁed by gender and initial body mass index
(BMI). We discounted costs (2006 US dollars) and QALYs by 3%
per annum. RESULTS: Under conservative assumptions, for a
woman aged 40 years with initial BMI of 35–40, LAGB has
lower average costs than LRGBY for the initial procedure
($15,470 versus $23,160) and complications ($3680 versus
$11,930), but results in less weight loss. ICERs are $13,990
and $14,690 for LAGB and LRGBY versus no treatment; and
$16,540 for LRGBY versus LAGB. Corresponding ICERs for
women with BMIs of 40–50 are $4860, $5150, and $5780.
ICERs for men are generally higher than those of women due to
shorter life expectancies. Sensitivity analyses show results to be
robust to reasonable variation in model parameters and over-
all parameter uncertainty. CONCLUSION: Both LAGB and
LRGBY provide signiﬁcant weight loss and are cost-effective
versus no treatment at conventionally-accepted thresholds for
medical interventions. Accordingly, choice between the two pro-
cedures can be based on other factors such as patient or provider
preference.
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OBJECTIVE: To analyze the economic consequences on staff
time in post-operative wards in Sweden and Denmark of two
modalities for treatment of post-operative pain, the fentanyl
HCL iontophoretic transdermal system (fentanyl ITS) versus
patient controlled intravenous analgesia (IV-PCA). METHODS:
Current postoperative pain management is labor intensive. Fen-
tanyl ITS is a new modality for moderate-to-severe postoperative
pain. Clinical efﬁcacy and side effects incidence have been
reported as mainly the same for fentanyl ITS and IV-PCA in
several randomized clinical trials. A cost analysis was therefore
performed. Staff resources in post-operative wards were calcu-
lated based on ﬁndings from a Nordic Delphi panel where the
participants (nurses and anesthesiologists) from Sweden and
Denmark working with post-operative patients should determine
the total time required to complete all tasks involved in fentanyl
ITS and IV-PCA use and assess differences in staff time between
the alternatives. The panelists identiﬁed the following tasks: set
up, routine patient care, dosing, routine replacement, trouble-
shooting, and discontinuation of post-operative pain manage-
ment. Staff costs were calculated based on ofﬁcial wages statistics
for specialists and nurses in postoperative care. Costs were cal-
culated in 2007 prices. RESULTS: Based on the panel informa-
tion, the total post-operative staff time requirements per patient
was 70 minutes for fentanyl ITS versus 146 minutes for IV-PCA.
Most staff resources were spent on set up and routine patient care
for both treatment alternatives. The post-operative staff cost per
patient was calculated at €27 and €57 in Sweden and €31 and
€66 in Denmark, respectively. CONCLUSION: The staff costs of
post-operative management in post-operative wards with fenta-
nyl ITS is 53% (€30) lower per patient in Sweden and 53% (€35)
lower in Denmark compared with IV-PCA. Additional health-
economic analyses of total resources used for post-operative pain
management, including material costs, based on clinical obser-
vations would be valuable.
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OBJECTIVE: Corticosteroids, IVIG and Anti-D can be used as
ﬁrst-line therapy for the treatment of ITP. After review of the
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